UNITED THERAPEUTICS CORP (UTHR)

US91307C1027 - Common Stock

359.58  -0.58 (-0.16%)

After market: 359.58 0 (0%)

Buy % Consensus

77

ChartMill assigns a Buy % Consensus number of 77% to UTHR. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 401.61. This target is 11.69% above the current price.
UTHR was analyzed by 22 analysts. The buy percentage consensus is at 77. So analysts seem to be have mildly positive about UTHR.
In the previous month the buy percentage consensus was at a similar level.
UTHR was analyzed by 22 analysts, which is quite many. So the average rating should be quite meaningful.

Price Target & Forecast

Price Low Median Mean High 359.58305.02393.32401.61630.00 - -15.17% 9.38% 11.69% 75.20%
Up and Down Grades
Date Firm Action Rating
2024-11-01 Goldman Sachs Maintains Neutral -> Neutral
2024-10-31 Ladenburg Thalmann Maintains Buy -> Buy
2024-10-31 Argus Research Maintains Buy -> Buy
2024-10-31 Oppenheimer Maintains Outperform -> Outperform
2024-10-31 HC Wainwright & Co. Maintains Buy -> Buy
2024-10-21 TD Cowen Maintains Buy -> Buy
2024-09-23 Jefferies Maintains Buy -> Buy
2024-08-28 Oppenheimer Maintains Outperform -> Outperform
2024-08-20 Wells Fargo Maintains Overweight -> Overweight
2024-08-01 B of A Securities Maintains Underperform -> Underperform
2024-08-01 HC Wainwright & Co. Reiterate Buy -> Buy
2024-07-25 HC Wainwright & Co. Maintains Buy -> Buy
2024-07-11 TD Cowen Maintains Buy -> Buy
2024-07-11 Morgan Stanley Downgrade Overweight -> Equal-Weight
2024-07-08 UBS Maintains Buy -> Buy
2024-06-12 Wells Fargo Maintains Overweight -> Overweight
2024-05-21 JP Morgan Maintains Overweight -> Overweight
2024-05-03 Goldman Sachs Maintains Neutral -> Neutral
2024-05-02 Oppenheimer Maintains Outperform -> Outperform
2024-05-02 HC Wainwright & Co. Reiterate Buy -> Buy
2024-03-07 Wells Fargo Maintains Overweight -> Overweight
2024-02-22 Wedbush Reiterate Outperform -> Outperform
2024-02-22 HC Wainwright & Co. Reiterate Buy -> Buy
2024-02-12 Goldman Sachs Upgrade Sell -> Neutral
2024-02-05 Leerink Partners Initiate Outperform
2023-11-02 Wedbush Maintains Outperform -> Outperform
2023-11-02 JP Morgan Maintains Overweight -> Overweight
2023-11-02 Morgan Stanley Maintains Overweight -> Overweight
2023-08-03 Ladenburg Thalmann Maintains Buy -> Buy
2023-08-03 Wedbush Maintains Outperform -> Outperform